Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Oracle Named Top Software Vendor for Life Sciences

By Drug Discovery Trends Editor | June 22, 2009

In a new report, IDC Health Insights, an advisory services and market research firm focused on the healthcare and life science markets, ranked Oracle as the number one vendor for enterprise life sciences software applications. The Life Science Software Top 10 identifies the 10 leading enterprise and specialty software vendors serving the sector based on enterprise life science software license revenue.

The report cites Oracle’s increased commitment and focus on life sciences for driving its leading share of the $2.95 billion that IDC Health Insights estimates is spent annually on software in the life sciences sector. According to report, “Oracle easily topped the chart, with nearly $60 million more than the second-place SAP.” The ranking is based solely on software license revenue derived from life sciences customers, and the study examined only enterprise solutions, which included: business intelligence/analytics, clinical software, customer relationship management (CRM), content management, revenue management/enterprise resource planning (ERP), human resources (HR), manufacturing, supply chain management, product lifecycle management (PLM), research and development (R&D) informatics and R&D discovery platforms.

“Oracle’s fast-paced acquisition strategy, coupled with its increased commitment and focus on the life sciences via its new Health Sciences Global Business Unit has paid big dividends, which have helped to drive its success in the life science industry,” wrote Eric Newmark, Research Manager, IDC Health Insights, in the report.

Date: June 22, 2009
Source: Oracle 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE